Similarly, first reports of the safety and efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS-G12C NSCLC have suggested poor response rates in patients that previously progressed on ICI, at least in part due to severe combination toxicities (11). This evidence concerns the gene KRAS and non-small cell lung carcinoma.